Sale!

Ocrevus (Ocrelizumab Injection) 300 mg / 10 ml

$2,894.58 $2,521.30

Category:

Description

Ocrevus (Ocrelizumab Injection) 300 mg / 10 ml

Ocrevus (Ocrelizumab Injection) 300 mg / 10 ml

Infusion Reactions (IRs)

• OCREVUS can cause IRs, which can include pruritus, rash, urticaria, erythema, bronchospasm, throat irritation, oropharyngeal pain, dyspnea, pharyngeal or laryngeal edema, flushing, hypotension, pyrexia, fatigue, headache, dizziness, nausea, and tachycardia
• In MS clinical trials, the incidence of IRs in OCREVUS-treated patients (who received methylprednisolone [or an equivalent steroid] and possibly other pre-medication to reduce the risk of IRs prior to each infusion) was 34%-40%, with the highest incidence with the first infusion. There were no fatal IRs, but 0.3% of OCREVUS-treated MS patients experienced IRs that were serious, some requiring hospitalization
• Observe patients treated with OCREVUS for IRs during the infusion and for at least one hour after completion of the infusion. Inform patients that IRs can occur up to 24 hours after the infusion

Reducing the Risk of IRs and Managing IRs

• Administer pre-medication (eg, methylprednisolone or an equivalent corticosteroid, and an antihistamine) to reduce the frequency and severity of IRs. The addition of an antipyretic (eg, acetaminophen) may also be considered
• Management recommendations for IRs depend on the type and severity of the reaction
– For life-threatening IRs, immediately and permanently stop OCREVUS and administer appropriate supportive treatment
– For less severe IRs, management may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment

 

 

ADVERSE REACTIONS

Infusion Reactions

Infections

Malignancies

Delayed or Missed Doses

• If a planned infusion of OCREVUS is missed, administer OCREVUS as soon as possible; do not wait until the next scheduled dose. Reset the dose schedule to administer the next sequential dose 6 months after the missed dose is administered
• Doses of OCREVUS must be separated by at least 5 months

 

Reviews

There are no reviews yet.

Be the first to review “Ocrevus (Ocrelizumab Injection) 300 mg / 10 ml”

Your email address will not be published. Required fields are marked *